For the past two decades, hematopoietic cell transplantation (HCT) has been used as effective therapy for selected inherited metabolic diseases (IMD) including Hurler (MPS IH) and Maroteaux-Lamy (MPS VI) syndromes, childhood-onset cerebral X-linked adrenoleukodystrophy (X-ALD), globoid-cell leukodystrophy (GLD), metachromatic leukodystrophy (MLD), a-mannosidosis, osteopetrosis, and others. Careful pre-HCT evaluation is critical and coordinated, multidisciplinary follow-up is essential in this field of transplantation. The primary goals of HCT for these disorders have been to promote long-term survival with donor-derived engraftment and to optimize the quality of life. Guidelines for HCT and monitoring are provided; a brief overview of long-term results is also presented.
In 1968, Fratantoni and Neufeld laid the foundation for our understanding of transferable lysosomal enzymes by demonstrating cross-correction of defects in cocultures of fibroblasts from Hurler and Hunter syndrome patients. 1 This observation and the later demonstration of correction by lymphocyte extracts or serum 2, 3 led Hobbs 4 to trial hematopoietic cell transplantation (HCT) as a permanent source of enzyme in a Hurler patient. The dramatic improvement effected in the disease phenotype has resulted in two decades of HCT for many other inherited metabolic diseases (IMD). [5] [6] [7] There have been many surprises along the way. From the impressive results in Hurler syndrome, 8, 9 it was expected that all mucopolysaccharide (MPS) disorders could be alleviated by HCT. Sadly, among these other MPS subtypes, benefit from HCT only appears to be significant for MPS VI (Maroteau-Lamy) 10, 11 and VII (Sly) , 12 although the reasons for this remain unclear. However, promising results have been obtained in various other disorders. In some, these could be anticipated (eg, metachromatic 7 and globoid-cell leukodystrophies 5 because of their lysosomal enzyme basis) but in others (eg, X-linked adrenoleukodystrophy 6 ), the mechanism underlying the success of timely HCT remains enigmatic even as our understanding of the disease pathogenesis evolves.
Evaluation of the true long-term value of HCT has been difficult for a variety of reasons: (a) Most diseases have a wide spectrum of clinical phenotype, which can be difficult to predict at diagnosis. (b) Benefit varies between organ systems. Reticuloendothelial organs such as liver and spleen often shrink quickly as engorged macrophages take up enzyme; however, CNS improvement is slower because of turnover of microglia and their replacement by donorderived cells. 13 The latter may explain the typical 'incubation period' of 6-12 months post-HCT before CNS deterioration is stabilized. 6 Unfortunately, there is little impact of HCT on bone disease, 14 presumably because of poor enzyme penetration into chondrocytes and the failure to correct or replace osteocytes. (c) Numerous aspects of the transplant affect outcome, for example, donor enzyme level, degree and persistence of donor chimerism, posttransplant complications, especially GVHD, 8, 9 and occasionally antibody formation against the novel protein to which the patient does not have tolerance.
Only now, with the benefit of years of follow-up and sufficient patients of each disease and phenotype transplanted, is it possible to draw conclusions for the commoner diseases transplanted. In this mini review, we summarize the impact of HCT on these candidate diseases, outlining recommended indications and contraindications. These must be seen in the context of emerging technology and may evolve as either transplantation techniques improve or alternative therapies emerge. For example, we have highlighted approaches such as enzyme replacement therapy (ERT) and mesenchymal stem cell infusion where these are under trial or development. We would stress that the following comments are only guidelines. In such complex diseases a decision to transplant can only be taken after extensive assessment, discussion, and counseling between metabolic and transplant experts and patients and their families.
Mucopolysaccharidosis (MPS)
The MPS disorders are a family of inherited disorders caused by deficiency of lysosomal enzymes needed to degrade glycosaminoglycans (GAGs) and are classified as types I-VII. 15 MPS I has a spectrum of subtypes ranging from mild (Scheie, MPS IS), though moderate (HurlerScheie, MPS IHS) to severe (Hurler, MPS IH). 15 
Hurler syndrome (MPS IH)
MPS IH is characterized by progressive mental retardation and hydrocephalus, frequent ear infections and auditory impairment, corneal clouding, sleep apnea, cardiopulmonary disease (including thickened valves, coronary artery narrowing, pulmonary hypertension, and congestive heart failure), hepatosplenomegaly, and severe skeletal abnormalities (termed dysostosis multiplex). These result in substantial morbidity and early death, typically occurring between 5 and 15 years of age. 15 Engraftment after HCT in Hurler patients leads to rapid reduction in GAG substrate in liver, tonsils, conjunctiva, CSF, and urine. 4, [16] [17] [18] As a consequence, obstructive airway symptoms are dramatically reduced 19, 20 together with hepatosplenomegaly 4, 21 and corneal clouding 16 , hydrocephalus is either prevented or stabilized 22, 23 , hearing improves in many children 24 and heart failure and tachyarrhythmias are eliminated by 1 year after successful HCT. 25, 26 Myocardial muscle function is stabilized or improved and coronary artery patency has been documented as long as 14 years after HCT. 27 However, some disease features show much poorer response because of poor penetration of a-l-iduronidase into the relevant tissue. Principal among these is the dysostosis multiplex, 14 and successfully transplanted children often require major orthopedic surgery for genu valgum, acetabular hip dysplasia, kyphoscoliosis, carpal tunnel syndrome, and trigger digits. [28] [29] [30] [31] These problems need careful monitoring and appropriate intervention, although the optimal timing of the latter is still debated. Further intellectual and developmental deterioration may occur, especially in the first year post transplant (possibly aggravated where donor enzyme levels are low as in heterozygotes). Cardiac valvular deformities persist and can progress. 32 The positive changes mostly occur rapidly in the early years after HCT and greatly improve the quality of life. However, the orthopedic and CNS problems may have major adverse impact from the age of 5 years. These factors must be taken into account alongside a relatively high incidence of primary and secondary graft failure. 4, 8, 9, [33] [34] [35] [36] The etiology of graft failure is unclear although aberrant processing of busulfan does not appear to be responsible. 37 This increases the transplant-related mortality and means that many children require repeat procedures. 36 A decision to transplant in MPS IH therefore requires extremely careful patient assessment and family counseling especially where alternative donors are to be used. It is critical to perform the transplant as early as possible, ideally before 18 months of age, while intellectual function is relatively well preserved.
8,9 Also, ongoing intensive physical, occupational, and speech therapy are essential to optimizing development before, during, and after HCT Hurler/Scheie and Scheie syndromes (MPS IH/S and MPS IS)
The indication for HCT is less clear in these phenotypes of MPS I because of the much slower disease course. 15 In MPS IH/S, the central nervous system deterioration can be insidious; for MPS IS life expectancy can extend into the fourth and fifth decades. It seems likely that enzyme replacement therapy 38 will become the mainstay of therapy for these children since lack of CNS penetration of administered enzyme is less crucial than in MPS IH. However, this may change if transplantation technology improves substantially, especially with the use of less intensive conditioning regimens.
Hunter syndrome (MPS II)
MPS II also comes in a range of phenotypes, some being relatively mild. 15 Unfortunately, severity is difficult to predict accurately at diagnosis. This may explain the presence of several case reports (all with relatively short follow-up), suggesting a beneficial effect from HCT. [39] [40] [41] However, there have also been many extremely disappointing outcomes from transplants. 23, 42, 43 It is the firm belief of the authors, and of many metabolic physicians experienced in following such children, that MPS II is not an appropriate indication for HCT. The reasons for the poor CNS responses (as in MPS III) remain unclear.
Sanfilippo syndrome (MPS III)
MPS III patients have progressive neurodevelopmental delay but with relatively few somatic manifestations. 15 Successful HCT performed early in the MPS III disease course does not seem to ameliorate neuropsychological deterioration significantly.
44-46

Morquio syndrome (MPS IV)
Patients with MPS IV exhibit severe dysostosis multiplex, but typically have preserved intellectual function. 15 At this time, there is no role for HCT since skeletal deformities can not be helped to any appreciable extent. 23 
Maroteaux-Lamy syndrome (MPS VI)
MPS VI is characterized by the onset of hydrocephalus and subsequent mental decline, cardiopulmonary dysfunction, hepatosplenomegaly and dysostosis multiplex; 15 the disease has mild and severe phenotypes. Reported benefits of HCT in MPS VI include enzymatic and biochemical correction, resolution of hepatosplenomegaly, stabilization of cardiopulmonary function, and improvement of visual acuity and joint mobility.
10,11,40 All phenotypes of MPS VI are associated with reduced life expectancy and should therefore be considered candidates for HCT or ERT.
Sly syndrome (MPS VII)
MPS VII, in certain circumstances, can be ameliorated by HCT provided that the neuropsychological and clinical status of the patient is good at the time of transplant.
12
Leukodystrophies and other white matter diseases Cerebral x-linked adrenoleukodystrophy (X-ALD) X-ALD 47,48 is a peroxisomal disorder involving defective boxidation of very long-chain fatty acids (VLCFA). Phenotypes vary in severity from pure Addisonian presentations without obvious CNS involvement, 49 through the insidious adult-onset form (adrenomyeloneuropathy (AMN)), adolescent and adult onset cerebral X-ALD to the rapidly dementing and fatal childhood onset cerebral form at most severe. Approximately 40% of boys with X-ALD will develop childhood cerebral disease. 47 The remaining boys are likely to develop AMN during the third or fourth decades with or without cerebral involvement. There does not appear to be a role for HCT in AMN alone based upon the nature of the disease (an axonopathy) and limited HCT experience in several cases.
HCT must be reserved for boys/men who have early yet definite evidence of cerebral disease as determined by brain magnetic resonance imaging 50 (MRI). In the near future, it is anticipated that magnetic resonance spectroscopy (MRS) will supplant MRI for the earliest detection of cerebral disease. [51] [52] [53] [54] A timely diagnosis is unlikely to occur in males identified from disease signs and symptoms because of the rapidly progressive character of cerebral X-ALD, 47 the expected delays in performing medical evaluations and confirming the diagnosis. However, boys less than 15 years of age diagnosed with X-ALD because of positive family history yet still symptom free can and should be monitored serially for the earliest evidence of demyelination. 55 These monitoring tests include gadolinium-enhanced brain MRI scans 50, 56 at intervals of 6 months or less to evaluate for cerebral demyelination on T2-weighted images, neuropsychological measures, and endocrinologic tests to evaluate for adrenal insufficiency (ie, Addison's disease). It appears that an MRI severity score as low as 2-3 and/or gadolinum enhancement 50 in a boy less than 10 years of age with X-ALD, is highly predictive (approaching 90%) of subsequent progressive cerebral demyelination. It is strongly suggested that such boys undergo HCT as soon as possible. Conversely, boys without evidence of abnormality on brain MRI should be monitored and not transplanted given the likelihood of not developing childhood cerebral form of X-ALD 47 (vide supra). The 5 to 10-year follow-up of 12 boys with childhoodonset cerebral X-ALD shows the long-term beneficial effect of HCT when the transplant is done at an early stage of disease. 6, 57, 58 Outcome measures included neuroradiologic assessment of demyelination, neurologic examination, and neurocognitive testing including verbal intelligence and performance (nonverbal) abilities. Unfortunately, the typical boy with parietal-occipital demyelination who is diagnosed due to clinical symptomatology (ie, not at an early stage of disease) has relatively spared verbal intelligence, visual processing difficulties, neurologic impairments in one or more of the following areas -vision, hearing, speech, and gait; and an MRI severity score always 47 and usually X11. The HCT and disease-specific outcomes in these boys have been very discouraging with many dying of progressive ALD. 50, 55, 56 For survivors, there are permanent, severe neurologic, and neuropsychologic sequelae; quality of life is compromised. Clearly, as currently practiced, HCT has not been successful for these patients.
Globoid-cell leukodystrophy (GLD)
GLD is characterized by periventricular demyelination and has two major phenotypes: (1) early onset also known as Krabbe disease and (2) late onset -juvenile and adult forms. 59 With appropriate timing and use of HCT, GLD can be effectively treated in late onset cases with normalization of CSF protein, stabilization of the neurologic examination, neuropsychologic function, and the extent of demyelination on MRI. 5 However, to date, Krabbe disease, if diagnosed antenatally, can only be ameliorated if HCT is performed in the neonatal period.
5,60
Metachromatic leukodystrophy (MLD) MLD, definitively diagnosed based upon both leukocyte arylsulfatase A deficiency and increased urinary sulfatides (in order to exclude patients with pseudodeficiency of arylsulfatase A), 61 cannot be treated effectively by HCT if neuropsychologic and/or neurologic signs are advanced or in late-infantile disease. [62] [63] [64] [65] HCT is recommended in presymptomatic patients or while neuropsychologic function and independence in activities of daily living remain good. [63] [64] [65] [66] Late infantile MLD may be helped if HCT occurs early in the first year of life following early postnatal or pre-natal diagnosis. 67 Koc et al 68 are investigating the role of mesenchymal stem cell infusion for MLD (See the Clinical care guidelines and future directions section).
Other leukodystrophies: Pelazeus-Merzbacher, Zellweger syndrome, Vanishing white matter disease, etc
To date, there has been neither experience nor a rationale developed for the use of HCT for any of the following leukodystrophies: Pelizaeus-Merzbacher, 69 Zellweger syndrome, 70, 71 and vanishing white matter disease.
72,73
Glycoprotein metabolic disorders
Fucosidosis
The extremely limited HCT experience in fucosidosis (ie, probably less than 10 HCT cases in the world) precludes any definitive statement about the outcomes. HCT performed early in the disease course may be beneficial.
74-76
Gaucher disease types I, II, III
HCT is effective in alleviating most disease manifestations of Gaucher including arresting further neuropsychological deterioration in type III (Norbottnian) disease [77] [78] [79] [80] [81] and greatly reducing skeletal problems in severe early onset type I disease. 34, [82] [83] [84] HCT is not currently regarded as first-line treatment because of the low morbidity of ERT. 85, 86 This approach may change in type III disease as ERT results are closely scrutinized and if HCT techniques improve. 87 The only experimental indication for HCT at present is in type III children who deteriorate neurologically and/or have pulmonary compromise while on ERT. 87, 88 a-mannosidosis At this time, fewer than 20 cases have been transplanted in the world. Pulmonary complications may be increased during the first several months after HCT. Early and later follow-up (ie, at X4 years) in several cases suggests that neurocognitive and cardiopulmonary function have been preserved, implying that HCT has had a favorable impact on the natural history of a-mannosidosis.
75,89
Aspartylglucosaminuria (AGU)
Four Finnish patients with AGU received HCT; 90 recent longer-term follow-up raises questions about the degree of benefit from HCT. 91 
Miscellaneous disorders
Neuronal ceroid lipofuscinosis (NCL)
Two forms of NCL (ie, NCL 1 and 2) are recognized as true lysosomal enzyme storage disorders (see Table 1 ), suggesting that HCT could be successful. 92 However, this has not been borne out by the only presymptomatic HCT performed in NCL 2 or by animal model transplant studies. [93] [94] [95] [96] Additional data are needed.
Niemann-Pick (NP, types A, B, and C)
NP type A is not amenable to effective treatment with HCT because of its rapid progression; 97, 98 there is limited experience suggesting that HCT ameliorates NP type B. 99 It should be noted that ERT clinical trials are planned for NP type B. The case report describing a patient with NP type C treated with HCT is not encouraging. 100 
Mucolipidosis, type II (I-cell disease)
Historical experience with HCT for I-cell disease 101 was initially only in patients with end-stage cardiopulmonary disease. 40, 102, 103 Over the past 5 years, three patients (0.3-1.7 years of age at HCT) have been transplanted at the Universirty of Minnesota. 104 The early follow-up has shown good cardiopulmonary function in two patients while one has developed pulmonary hypertension. All children remain mildly to moderately neurodevelopmentally delayed and are receiving appropriate additional educational resources.
Gangliosidoses
The G M2 gangliosidoses include Tay-Sachs disease, Sandhoff disease, and G M2 activator deficiency and demonstrate widely varying clinical phenotypes. Infantile onset, rapidly progressive neurodegenerative disease leads to death by 4 years (classic Tay-Sachs, Sandhoff and G M2 activator deficiency), while later onset subacute or chronic forms show more slowly progressive neurologic conditions compatible with survival into late childhood, adolescence, or even long-term survival. HCT does not appear to successfully treat these disorders. However, future therapy that combines direct CNS intervention with HCT may ultimately prove beneficial. 23, 105 . G M1 gangliosidosis typically presents in infancy; however, later onset forms are also recognized (ie, type 2 disease). 106 HCT may be beneficial in type 2 patients with suitable neurologic and neuropsychologic function, though not in type 1 infants. 107 
Malignant infantile osteopetrosis (MIOP)
Absence or defective function of osteoclasts causes this disease of bone sclerosis. 108 There are many animal models, both spontaneously occurring and created by gene knockouts, although few seem to have overlap with human disease. [109] [110] [111] It is becoming apparent that there are also multiple causes in humans. 110, 112, 113 The commonest is mutation of a gene encoding a vacuolar proton pump, which is responsible for approximately 50% of human cases.
113,114
All of the described genetic causes of osteopetrosis are defects in acidification and are not abnormalities of osteoclast differentiation. However, the phenotypic variation of the disease suggests that additional gene defects will be defined.
Some other forms of MIOP are metabolic diseases with a neurological component. These include carbonic anhydrase II deficiency 115 (renal tubular acidosis and cerebral calcification) and a severe disease characterized by early onset of spasticity and death with eosinophilic inclusion bodies seen on CNS pathological examination (here termed 'neuronopathic' osteopetrosis since it mimics neuronal ceroid lipofuscinosis). 116, 117 In both diseases HCT abolishes bone sclerosis. However, it has no impact on neurodegenerative disease in the latter form 116, 118 and CNS amelioration in CAII deficiency seems unlikely. 115, 119 . Therefore, these issues must be considered as transplantation is discussed in affected children.
Distinguishing children with neuronopathic osteopetrosis from those with the conventional disease is difficult, especially since these children are often irritable. This can be because of occult hypocalcemia in the first two months, 120 multiple fractures, hydrocephalus, or raised intracranial venous pressure (because of bony encroachment on the jugular foramen). There should be strong suspicion of primary neurological disease if irritability does not respond to correction of hypocalcemia and analgesia. Successful allogeneic HCT is currently the only therapy capable of producing long-term benefit in children. [121] [122] [123] [124] [125] This results in bone remodeling, restoration of growth, and reconstitution of normal hematopoiesis and neutrophil function. Early HCT offers the best possibility for limiting neurosensory defects and impaired growth. Serious risks include high frequencies of graft rejection, veno-occlusive disease, and the newly recognized problem of severe pulmonary hypertension. The latter is easy to mistake for pneumonitis but affects up to 25% of transplanted patients (CG Steward et al, submitted for publication). Results using alternative donors have typically yielded poor results but megadose stem cell transplants from family donors matching at least one haplotype are now giving more promising results. 126 
Wolman disease
Deficiency of acid lipase in Wolman disease leads to massive accumulation of cholesteryl esters and triglycerides in most body tissues. HCT has been performed in a small number of patients. 127 One engrafted surviving patient has been reported. 128 Clinical care guidelines and future directions
Comprehensive, multidisciplinary care
The best outcomes have occurred following an expeditious and timely referral to a transplant center. 6, 8, 9, 43, 58, 64, 75 Comprehensive, multidisciplinary specialist care coordinated through this center, with significant experience in the peri-and post-HCT management of these complex diseases is essential. Specific members of such a team might include a transplant physician who interacts directly with neurologists, geneticists, neuropsychologists, neuroradiologists, ophthalmologists, audiologists, otolaryngologists, pulmonologists, cardiologists, hand and orthopedic surgeons, pediatric surgeons, endocrinologists, anesthesiologists, radiation therapists, pharmacologists, and infectious disease specialists prior to transplant and during annual or every 2-year follow-up evaluations.
Donor and stem cell selection
The source of stem cells could be bone marrow, umbilical cord blood, or peripheral blood. Identification of optimal graft characteristics for these various stem cell sources is ongoing. Specifically, the role of bone marrow graft engineering (T-cell depletion), cell dose (ie, nucleated cells, CD34+ cells), HLA-matching, timing of transplant, and availability are all under study. Selection of the donor will initially focus on the availability of an HLA-matched sibling. If one is not available, alternative donors would include a closely matched unrelated graft or perhaps a graft from a haploidentical relative. There is increasing interest in and use of umbilical or peripheral blood as a source of stem cells. The experience is too limited at this time to draw any conclusions regarding engraftment, incidence or severity of graft-versus-host disease (GVHD), or diseasespecific outcomes using these sources of stem cells in IMD patients. However, consideration should be given to their use under appropriate circumstances. It is highly recommended that the relevant leukocyte enzyme activity be determined in the donor. Questions persist regarding the use of a heterozygous (ie, carrier) donor. No definitive comparison of outcomes has been performed, although higher enzyme levels achieved in the recipient have correlated with better outcomes in Hurler patients.
9,129
Preparative regimen A variety of preparative regimens have been used for these disorders. 8, 9, 58, 130 No clear preferred regimen has been identified. However, transplanters must be aware of the patient's medical condition and the potential for significant regimen-related toxicity because of disease-specific organ system problems, as well as the propensity for disease progression, particularly in the CNS. 8,9,36,58 Less intensive conditioning regimens are being explored and may play a role in the treatment of selected patients and diseases.
Alternative stem cells
Koc et al 68 have investigated bone marrow-derived mesenchymal stem cells (MSCs) in 13 patients (Hurler: 5; MLD: 3; X-ALD: 2; Gaucher, MPS VI, GLD: 1 each) from 1 to 14 years after allogeneic HCT and found that MSCs isolated from recipients are not of donor genotype and have persistent phenotypic defects despite successful donor-type hematopoietic engraftment. Whether culture-expanded normal MSCs can be successfully transplanted into patients with IMD and provide therapeutic benefit was unclear. Koc et al 131 have recently reported on allogeneic MSC infusion for treatment of 11 patients (MLD: 6, Hurler: 5). There was no MSC infusion-related toxicity, delayed toxicity, or GVHD at a median clinical follow-up of 2 years. The percentage of MSCs observed to be of donor origin was low (ie, 0.4-2.0%). Although there was no clinically apparent change in patients' overall health and no objective change in mental and physical development after MSC infusion, in four of six MLD patients, nerve conduction velocity was faster after MSC infusion. Bone mineral density was either maintained or slightly improved in all patients. They concluded that donor allogeneic MSC infusion was safe and may be associated with amelioration of disease pathophysiology in some tissues. Growth of other specialized cells including osteoblasts, chondroblasts, neurons, oligodendrocytes, and astrocytes is under study. It can be anticipated that there would be the potential for infusion or direct introduction of such cells to correct existing defects.
Enzyme replacement therapy
Enzyme replacement therapy (ERT) is currently available for a number of IMD and is in development for many others. The role of pre-HCT ERT is yet to be explored but may serve to decrease the incidence and/or severity of transplant-and disease-related complications during the peritransplant period. There may also be a role for the use of ERT after HCT.
Gene therapy
With time, gene therapy could obviously become an adjunct to or even replace HCT. However, pitfalls in the areas of transducing stem cells, achieving high levels of gene expression, assuring appropriate localization of the gene product as well as sustained gene expression must be addressed.
Conclusions
Transplant therapy can be effective for selected inherited metabolic diseases including MPS syndromes (ie, Hurler, Maroteaux-Lamy, and Sly syndromes), leukodystrophies (ie, childhood and adolescent cerebral X-ALD, GLD, and MLD), fucosidosis, a-mannosidosis, Gaucher disease, Niemann-Pick type B, and malignant infantile osteopetrosis. To increase the likelihood of a good outcome, complex, multidisciplinary decision-making regarding whether to recommend HCT, when to do so, and how to provide optimal peri-and post-HCT care is essential. Transplant has led to favorable outcomes for many but not for all of these disorders. Improvements in HCT techniques and the development of novel stem cells will significantly impact the safety and efficacy of therapy as well as expand the list of candidate diseases. 
